



Theraclion's managers and employees invest in capital equity

Long-term alignment of the interests of company's executives and employees with those of its shareholders

Malakoff – June 29, 2015 – THERACLION (Alternext, FR0010120402 – ALTHE), a company specialized in leading-edge medical equipment for echotherapy, today announced that management and key employees have directly invested over €300,000 in Theraclion's capital equity by buying existing shares. This represents close to 60,000 shares acquired, accounting for 1.38% of total capital equity.

"I'm proud that so many of our employees have invested in Theraclion's capital equity. It underlines Theraclion's management and employees' confidence in the development of the Echopulse system and their commitment to expanding the client base. It represents the long-term alignment of the interests of the company's executives and employees with those of its shareholders while helping to attract and retain key executives and employees. Lastly, it reflects their commitment to the innovative echotherapy project", commented David Caumartin, CEO of Theraclion.

16 managers and employees in 25 people have invested in the Company's capital equity by purchasing Theraclion shares with their own resources. This will contribute to driving long-term Shareholder Value.

About Theraclion

Theraclion is a French company specializing in high-tech medical equipment using therapeutic ultrasound. Drawing on leading-edge technologies, Theraclion has designed and manufactured an innovative solution for echotherapy, the Echopulse®, allowing non-invasive tumor treatment through ultrasound-guided high-intensity focused ultrasound.

Theraclion is ISO 13485 certified and has received the CE mark for non-invasive ablation of breast fibroadenomas and thyroid nodules. Based in Malakoff, near Paris, France Theraclion has brought together a team of 25 people, 52 percent of whom are dedicated to R&D and clinical trials. For more information, please visit Theraclion's website: www.theraclion.com.

Theraclion is listed on Alternext Paris
PEA-PME Eligible
Mnemonic: ALTHE - ISIN Code: FR0010120402



Contacts:

Theraclion

David Caumartin

CEO

Tel.: +33 (0)1 55 48 90 70

david.caumartin@theraclion.com

NewCap

Financial Communications & Investors relations

Emmanuel Huynh / Valentine Brouchet

Tel.: +33 (0)1 44 71 94 94

theraclion@newcap.fr

Kalima

Press Relations

Estelle Reine-Adélaïde/ Florence Calba

Tel. : + 33 (0)1 44 90 82 54

era@kalima-rp.fr